Hidai H
Yokohama Dai-ichi Hospital, Kanagawa, Japan.
Kidney Int. 2000 Jul;58(1):363-73. doi: 10.1046/j.1523-1755.2000.00174.x.
In view of the growing dialysis population and the increasing reimbursement cost in the industrialized countries, a critical evaluation of the dialysis economy is warranted.
Data for the reimbursement and dialysis patients' statistics were collected from the National Medical Care Expenditure (NMCE), 1979-1996, which was published by the Japanese government, and the article "An overview of regular dialysis treatment in Japan," 1979-1998, by the Japanese Society for Dialysis Therapy, as well as unpublished data from the Yokohama Dai-ichi Hospital and 10 affiliated urban dialysis centers.
From 1979 to 1996, the dialysis population increased 5.2 times and the NMCE increased 2.5 times, whereas the end-stage renal disease (ESRD) payment increased only 1.8 times. Because of a drastic reduction in the dialyzer cost and the dialysis-related technical fee, both the percentage of ESRD-related payment within NMCE and ESRD payment per capita per year decreased from 5.4 to 4.1% and from 16.3 million yen to 5.6 million yen, respectively. Despite this drastic cost reduction, the patient survival and quality of life determined by the social rehabilitation rate did not decline.
The Japanese health insurance policy for dialysis management achieved a successful cost cut during the 1979-1996 period by using an incentive-based payment system toward quality care. However, the forthcoming further exponential increase in the dialysis population may put the dialysis economy and hence dialysis care quality in jeopardy. Effort must be made to reduce the ESRD-related cost through prevention of the progression of kidney diseases, propagation of renal transplantation, and internationalization of continuous ambulatory peritoneal dialysis and erythropoietin cost. A reduction in dialysis reimbursement, if necessary, must be achieved through an incentive-based system toward quality patient care.
鉴于工业化国家透析人群不断增加以及报销费用日益上涨,对透析经济进行严格评估很有必要。
报销数据和透析患者统计数据来自日本政府公布的《1979 - 1996年国家医疗保健支出》以及日本透析治疗学会的《1979 - 1998年日本定期透析治疗概述》一文,还有来自横滨第一医院及10家附属城市透析中心的未发表数据。
1979年至1996年期间,透析人群增长了5.2倍,国家医疗保健支出增长了2.5倍,而终末期肾病(ESRD)支付仅增长了1.8倍。由于透析器成本和透析相关技术费用大幅降低,ESRD相关支付在国家医疗保健支出中的占比以及人均每年的ESRD支付分别从5.4%降至4.1%,从1630万日元降至560万日元。尽管成本大幅降低,但由社会康复率决定的患者生存率和生活质量并未下降。
日本针对透析管理的医疗保险政策在1979 - 1996年期间通过基于激励的优质护理支付系统成功削减了成本。然而,即将到来的透析人群进一步指数级增长可能会危及透析经济,进而影响透析护理质量。必须努力通过预防肾脏疾病进展、推广肾移植以及使持续非卧床腹膜透析和促红细胞生成素成本国际化来降低与ESRD相关的成本。如有必要,必须通过基于激励的优质患者护理系统来降低透析报销费用。